PT891426E - Bicunina humana - Google Patents

Bicunina humana

Info

Publication number
PT891426E
PT891426E PT97915029T PT97915029T PT891426E PT 891426 E PT891426 E PT 891426E PT 97915029 T PT97915029 T PT 97915029T PT 97915029 T PT97915029 T PT 97915029T PT 891426 E PT891426 E PT 891426E
Authority
PT
Portugal
Prior art keywords
bicuna
human
human bicuna
Prior art date
Application number
PT97915029T
Other languages
English (en)
Portuguese (pt)
Inventor
Paul P Tamburini
Davis Gary
Katherine A Delaria
Christopher W Marlor
Daniel K Muller
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PT891426E publication Critical patent/PT891426E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
PT97915029T 1996-03-11 1997-03-10 Bicunina humana PT891426E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
PT891426E true PT891426E (pt) 2006-10-31

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97915029T PT891426E (pt) 1996-03-11 1997-03-10 Bicunina humana

Country Status (27)

Country Link
US (3) US6583108B1 (OSRAM)
EP (1) EP0891426B1 (OSRAM)
JP (2) JP3469584B2 (OSRAM)
KR (1) KR100356956B1 (OSRAM)
AR (3) AR006188A1 (OSRAM)
AT (1) ATE328083T1 (OSRAM)
AU (1) AU716923B2 (OSRAM)
BR (1) BR9708021A (OSRAM)
CA (1) CA2247888A1 (OSRAM)
CO (1) CO4600683A1 (OSRAM)
DE (1) DE69735996T2 (OSRAM)
DK (1) DK0891426T3 (OSRAM)
ES (1) ES2263174T3 (OSRAM)
HR (1) HRP970144B1 (OSRAM)
HU (1) HU226419B1 (OSRAM)
ID (1) ID16224A (OSRAM)
IL (1) IL126115A (OSRAM)
IN (1) IN192874B (OSRAM)
MY (1) MY120693A (OSRAM)
NZ (1) NZ331540A (OSRAM)
PA (1) PA8426301A1 (OSRAM)
PL (1) PL188387B1 (OSRAM)
PT (1) PT891426E (OSRAM)
SV (1) SV1997000018A (OSRAM)
TR (1) TR199801794T2 (OSRAM)
WO (1) WO1997033996A2 (OSRAM)
YU (1) YU8997A (OSRAM)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
DK1140150T3 (da) * 1998-12-22 2004-03-22 Bayer Ag Fremgangsmåde til accelerering af hastigheden af mucociliær clearance under anvendelse af en serinproteaseinhibitor af Kunitz-type
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000051624A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
EP1539985A4 (en) * 2001-11-05 2006-06-28 Curagen Corp THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
MXPA05007322A (es) 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
DE602004025380D1 (de) * 2003-10-10 2010-03-18 Multicell Technologies Inc Immortalisierte hepatozyten
JP2007536206A (ja) * 2003-10-16 2007-12-13 バイエル・ヘルスケア・エルエルシー 尿中トリプシンインヒビターを検出するためのモノクローナル抗体
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
US20060010098A1 (en) 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ATE551422T1 (de) 2005-02-18 2012-04-15 Angiochem Inc Aprotininpolypeptide zum transport einer verbindung durch die blut-hirn-schranke
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
AU2006332774A1 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
US20100063146A1 (en) * 2006-11-07 2010-03-11 Medof M Edward Method for treating disorders related to complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2170932A4 (en) * 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
MX355683B (es) * 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
AU2011204349C1 (en) 2010-01-06 2017-02-16 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MX2016010950A (es) 2014-02-24 2017-04-25 Takeda Gmbh Proteinas de fusion de inhibidor de tripsina urinaria (uti).
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
EP0439442B1 (en) 1990-01-25 1996-03-06 Washington University Factor x-laci hybrid protein
AU1581692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5747449A (en) 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
AU5684594A (en) 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (en) 1994-07-21 1996-02-08 The Green Cross Corporation Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
JPH11504938A (ja) 1995-05-08 1999-05-11 サイオス インク． クニッツ型プロテアーゼ阻害因子
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
DK0891426T3 (da) 2006-10-02
IL126115A (en) 2007-03-08
AR058982A1 (es) 2008-03-05
HUP9902698A3 (en) 2001-06-28
CA2247888A1 (en) 1997-09-18
YU8997A (sh) 1999-09-27
HU226419B1 (en) 2008-12-29
PA8426301A1 (es) 2000-05-24
HRP970144B1 (en) 2004-10-31
EP0891426B1 (en) 2006-05-31
AR006188A1 (es) 1999-08-11
KR100356956B1 (ko) 2003-03-15
US7452859B2 (en) 2008-11-18
US20030194398A1 (en) 2003-10-16
JP3469584B2 (ja) 2003-11-25
MY120693A (en) 2005-11-30
IL126115A0 (en) 1999-05-09
WO1997033996A2 (en) 1997-09-18
ID16224A (id) 1997-09-11
IN192874B (OSRAM) 2004-05-29
DE69735996T2 (de) 2007-02-15
KR19990087697A (ko) 1999-12-27
ES2263174T3 (es) 2006-12-01
EP0891426A2 (en) 1999-01-20
TR199801794T2 (xx) 2000-07-21
JP2004000208A (ja) 2004-01-08
NZ331540A (en) 1999-10-28
DE69735996D1 (de) 2006-07-06
US7019123B2 (en) 2006-03-28
JP2001521367A (ja) 2001-11-06
AU2207797A (en) 1997-10-01
ATE328083T1 (de) 2006-06-15
HUP9902698A2 (hu) 1999-11-29
CO4600683A1 (es) 1998-05-08
BR9708021A (pt) 1999-07-27
SV1997000018A (es) 1999-01-14
PL188387B1 (pl) 2005-01-31
WO1997033996A3 (en) 1997-11-13
AR053063A2 (es) 2007-04-18
AU716923B2 (en) 2000-03-09
HRP970144A2 (en) 1998-04-30
US6583108B1 (en) 2003-06-24
US20060172946A1 (en) 2006-08-03
PL328822A1 (en) 1999-02-15

Similar Documents

Publication Publication Date Title
PT891426E (pt) Bicunina humana
DE69739113D1 (de) Abdeckvorrichtung
ATE208395T1 (de) Thiophenopyrimidine
ATE262512T1 (de) Arylalkanoylpyridazine
ATE208773T1 (de) Chinoxalindione
NO985143D0 (no) Artropoderepellant
DE69729809D1 (de) Cyclopentanbutanolderivate
DE69735754D1 (de) Impedanz-abhängiger implantierbarer kardiovertierer defribillator
ID17978A (id) Pembuatan 6-aminokapronitril
FI964700A0 (fi) Mikroavkylningsapparat
DE69725330D1 (de) Herzschrittmacher
ID16330A (id) Pembuatan asetaldehide
ID17636A (id) Pembuatan 6-aminokapronitril
PT777494E (pt) Polipeptidos de quimiocina humana
KR970054675U (ko) 티슈용 케이스
ID17224A (id) Sediaan
FI962500L (fi) Formeri
ATE267568T1 (de) Epithese
FI2888U1 (fi) Paalileikkuri
FIU960347U0 (fi) Laitarakenne
BR9605291A (pt) Hidro-coleta
BR9600920A (pt) Otimizador-turbinado-nb
BR9604479A (pt) Gongorremo
BR9604349A (pt) Xapisqueira
BR9603978A (pt) Confort-let